In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Access

Set Alert for Market Access

China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms

China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.  

Asia Pacific China

Physician Behavioral Inertia: Innovation’s Greatest Enemy

Overcoming Inertia is a challenge. Physicians want novel and better medications and products, but evaluating and trying new products takes time and may involve risk. 

Commercial Market Access

In Times Of Adversity, Surgical Robot Developers Must Remain Sharp

Harsh economic conditions and increased competition are dictating that surgical robotics companies must quickly adopt new commercial strategies. In Vivo speaks to key players in the space to learn more.

Robotic Surgery Business Strategies

Rethinking Commercialization Models In The Age Of Pricing And Access Complexity

In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.

Commercial Innovation

Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?

Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new “Netflix” style subscription model for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space. 

Infectious Diseases C-Suite Speaks

Seres And Ferring Go Head-To-Head In Recurrent C. Difficile Market

After the historic approvals of Seres’ and Ferring’s microbiome-based treatments for recurrent Clostridioides difficile infection, the two companies are waiting to see who dominates the $1bn market. Physicians say patients will steer the choice of treatments.

Strategy Commercial

Singapore: A Country Punching Above Its Weight

With strong government support over the past two decades, the Singaporean life sciences industry has matured. Initially known as a manufacturing hub, Singapore’s innovation ecosystem is now thriving, but the challenge is to cultivate commercialization power.

Singapore Market Access

Boehringer Ingelheim’s Pagnotta On Adalimumab And Interchangeability

As Boehringer Ingelheim launches the first – and so far, only – interchangeable US adalimumab biosimilar, the firm’s biosimilar commercial brand lead Stephen Pagnotta talks about how the interchangeability designation puts the firm in a unique position when it comes to competing with Humira.

Commercial Strategies Biosimilars

In The Uncharted Waters Of AI, Healthcare Firms Keep A Sharp Lookout For Hidden Risks

A new report from legal and consultancy firm CMS shines a light on the healthcare industry’s adoption of emerging technology. Survey data reveal the aspirations and latent fears of healthcare innovators as they navigate through the maze of AI, IP and data. CMS partner Jeremy Mash explains the background.

Market Access Artificial Intelligence

Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 

Asia Pacific China

What Role Is There for Patients In Managed Access Deals?

Market access deals can make or break routine access to new treatments. So what happens when patient-centricity and deal-making meet? Leela Barham looks at the experience in England.

Market Access Pricing Strategies

From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs

Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.

US States Business Strategies

In Saudi Arabia, A Vision Of Healthcare Spurs Growth

As the Kingdom of Saudi Arabia reduces its dependence on oil as an export, one sector it is building up is the life sciences industry. The government is encouraging global companies to manufacture and invest domestically and they are improving their regulatory system and working with local players to enhance access to patients.

Saudi Arabia Emerging Markets

The E In ESG: Sustainability Goals Do Not Exempt Companies From Antitrust Compliance

Regulatory interventions are the preferred route for ensuring sustainability compliance, says the OECD. Legal firm CMS notes that some ESG objectives may be in contravention of antitrust law. The EU is preparing guidelines on horizontal competition with a renewed focus on sustainability.

Sustainability Market Access

‘Fail Quickly, Succeed Quickly’ – BioWales Profiles Value Proposition For Medtech Innovation

New policy initiatives and “can do” networking openness in Wales are persuading medtech and healthtech innovators to consider the merits of locating in Great Britain’s smallest home nation.

Market Access United Kingdom

For New RSV Shots, ‘Vaccine Fatigue’ Could Be One Of The Biggest Barriers

Pfizer and GSK are expected to gain approval and launch in time for this year’s flu season, but must educate public and physicians

Vaccines Approvals
See All